Hepatitis B vaccination in HIV-infected adults: Current evidence, recommendations and practical considerations

International Journal of STD and AIDS

Volumn 20, Issue 9, 2009, Pages 595-600

  Kim, H Nina ^a,b   Harrington, R D ^a   Crane, H M ^a   Dhanireddy, S ^a   Dellit, T H ^a   Spach, D H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

Hepatitis B vaccination; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; NEVIRAPINE; RECOMBINANT HEPATITIS B VACCINE; SENVAC HB; UNCLASSIFIED DRUG; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS REPLICATION;

ADULT; CD4 LYMPHOCYTE COUNT; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TIME FACTORS; VACCINATION;

EID: 69949191643     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009126     Document Type: Review

References (52)

1. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:571-577
2. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606
3. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163:454-459
4. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310 (Pubitemid 29168769)
5. Thio CL, Seaberg EC, Skolasky R Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926
6. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 8 December 2006;55:1-33; quiz CE31-34
7. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004;38:1478-1484
8. Dienstag JL, Werner BG, Polk BF, et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984;101:34-40
9. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982;307:1481-1486 (Pubitemid 13238769)
10. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988;109:101-105 (Pubitemid 18181437)
11. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis 2006;6:65 (Pubitemid 44173067)
12. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006;24:7124-7128 (Pubitemid 46107206)
13. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-214
14. Kim HN, Harrington RD, Van Rompaey S, Kitahata MM. Independent clinical predictors of hepatitis B vaccination in HIV-infected patients. Int J STD AIDS 2008;19:600-604
15. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007;25:5324-5329 (Pubitemid 46977535)
16. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045-1048 (Pubitemid 41368231)
17. Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008;40:54-58
18. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-685
19. Wilson CM, Ellenberg JH, Sawyer MK, et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001;29:123-129
20. de Vries-Sluijs TEMS, Hansen BE, van Doornum GJJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-294
21. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368-1375 (Pubitemid 35448965)
22. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-2908
23. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006;3:9 (Pubitemid 44309020)
24. Wong EK, Bodsworth NJ, Slade MA, Mulhall BP, Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996;7:490-494 (Pubitemid 27037409)
25. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2009; Epub ahead of print
26. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008;12:e77-e83
27. Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transpl 2002;2:965-969 (Pubitemid 36330227)
28. Playford EG, Hogan PG, Bansal AS, et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002;23:87-90
29. Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infect Control Hosp Epidemiol 1995;16:88-91
30. Shafran SD, Mashinter LD, Lindemulder A, Taylor GD, Chiu I. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. HIV Med 2007;8:295-299 (Pubitemid 46901528)
31. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18:1161-1165
32. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22
33. Bloom A, Jackson K, Kiviat A, Zheng H, Sax P, Gandhi R. Repeat Hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr 2009;50:110-113
34. Sasaki MG, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21:4545-4549 (Pubitemid 37315774)
35. Overton ET, Kang M, Umbleja T, et al. ACTG 5220: Hepatitis B Vaccine Responses in HIV-infected Persons Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Paper presented at: ICAAC/IDSA, 2008
36. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46:1310-1314 (Pubitemid 351589919)
37. Cheeseman SH, Davaro RE, Ellison RT, 3rd. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996;334:1272 (Pubitemid 26138006)
38. Sheng W-H, Kao J-H, Chen P-J, et al. Evolution of Hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007;45:1221-1229 (Pubitemid 47580325)
39. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-1384 (Pubitemid 41443405)
40. Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. 18 June 2008; available at: http://aidsinfo.nih.gov/contentfiles/Adult-OI.pdf (last accessed 11 November 2008)
41. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med 2009;150:40-44
42. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004;36:869-875
43. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006;20:1253-1260 (Pubitemid 44030373)
44. Tsui JI, French AL, Seaberg EC, et al. Prevalence and long-term effects of occult Hepatitis B virus infection in HIV-infected women. Clin Infect Dis 2007;45:736-740 (Pubitemid 47378888)
45. Grob P, Jilg W, Bornhak H, et al. Serological pattern 'anti-HBc alone': report on a workshop. J Med Virol 2000;62:450-455
46. Ural O, Findik D. The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. J Infect Oct 2001;43:187-190 (Pubitemid 34211100)
47. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988;8:766-770
48. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992;103:590-594
49. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005;191:1435-1441 (Pubitemid 40563354)
50. Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai 2006;89:2028-2034 (Pubitemid 44956681)
51. Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule: United States, October 2007-September 2008. Ann Intern Med 2007;147(10):725-729
52. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001;165:1063-1064 (Pubitemid 32964871)